tiprankstipranks
Trending News
More News >
Broncus Holding Corp. (HK:2216)
:2216
Hong Kong Market
Advertisement

Broncus Holding Corp. (2216) AI Stock Analysis

Compare
0 Followers

Top Page

HK:2216

Broncus Holding Corp.

(2216)

Rating:54Neutral
Price Target:
HK$2.50
▼(-9.09%Downside)
Broncus Holding Corp.'s stock score of 54 reflects a mixed outlook. The company's strong technical momentum is overshadowed by fundamental financial weaknesses, including profitability and cash flow challenges. The lack of earnings call data and corporate events limits additional insights.

Broncus Holding Corp. (2216) vs. iShares MSCI Hong Kong ETF (EWH)

Broncus Holding Corp. Business Overview & Revenue Model

Company DescriptionBroncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.
How the Company Makes MoneyBroncus Holding Corp. makes money by developing and selling its proprietary medical devices and solutions to healthcare providers and institutions. Its revenue model primarily consists of direct sales of its diagnostic and therapeutic products, as well as potential licensing agreements and partnerships with other medical technology firms. The company may also engage in research collaborations and receive funding or grants related to its innovative work in the pulmonary field. These partnerships and collaborations help Broncus expand its market reach and accelerate the commercialization of new technologies.

Broncus Holding Corp. Financial Statement Overview

Summary
Broncus Holding Corp. exhibits significant financial challenges with consistent revenue declines and negative profitability metrics. Despite a high gross profit margin and low debt leverage, the persistent net losses and poor cash flow generation weigh heavily on its financial health.
Income Statement
35
Negative
Broncus Holding Corp. displays a challenging income statement profile with consistent revenue declines from 2021 to 2024, despite experiencing a peak in 2020. The gross profit margin remains high at around 75.5% in 2024, reflecting efficient cost management relative to revenue. However, significant net losses and negative EBIT and EBITDA margins, particularly in 2024 with a net profit margin of -188.23%, indicate persistent profitability issues.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with a high equity ratio of 96.36% in 2024, suggesting good asset coverage by equity. The debt-to-equity ratio is low at 0.0019, indicating minimal leverage. However, the company has experienced declines in total assets and stockholder equity over time, posing potential risks if trends continue.
Cash Flow
30
Negative
Broncus Holding Corp. faces significant cash flow challenges. The operating cash flow to net income ratio indicates a disconnect between earnings and cash flow generation, as evidenced by zero operating cash flow in 2024. The lack of free cash flow growth and historically negative free cash flow further stress the company's liquidity position.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.13M10.26M9.41M10.89M3.26M
Gross Profit6.14M7.23M7.32M8.74M2.51M
EBITDA-18.96M-25.06M-25.51M-233.31M-45.95M
Net Income-15.30M-28.09M-28.04M-236.18M-48.79M
Balance Sheet
Total Assets175.90M195.81M221.94M252.81M39.88M
Cash, Cash Equivalents and Short-Term Investments98.82M156.88M187.91M227.21M18.79M
Total Debt318.00K2.35M1.47M1.95M6.12M
Total Liabilities6.42M10.44M8.48M10.39M162.32M
Stockholders Equity169.48M185.37M213.46M242.42M-120.51M
Cash Flow
Free Cash Flow-10.32M-26.84M-31.81M-33.38M-16.76M
Operating Cash Flow-10.00M-26.13M-30.95M-31.49M-15.59M
Investing Cash Flow-25.91M5.49M-87.57M-1.75M-1.09M
Financing Cash Flow-1.02M-1.46M-572.00K241.82M32.23M

Broncus Holding Corp. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.75
Price Trends
50DMA
2.20
Positive
100DMA
1.74
Positive
200DMA
1.16
Positive
Market Momentum
MACD
0.16
Negative
RSI
66.50
Neutral
STOCH
72.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Positive. The current price of 2.75 is above the 20-day moving average (MA) of 2.23, above the 50-day MA of 2.20, and above the 200-day MA of 1.16, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 66.50 is Neutral, neither overbought nor oversold. The STOCH value of 72.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2216.

Broncus Holding Corp. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
61
Neutral
HK$1.96B-1.28%17.45%85.71%
54
Neutral
HK$1.45B-8.64%-20.99%45.74%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
52
Neutral
HK$3.06B-2.19%5.32%89.43%
49
Neutral
HK$771.34M-18.64%41.62%-22.27%
HK$2.76B-3.13%
46
Neutral
HK$1.27B-27.82%-6.12%0.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2216
Broncus Holding Corp.
2.70
2.16
400.00%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.32
0.56
73.68%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.87
1.10
62.15%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.35
2.77
77.37%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
2.82
-2.80
-49.82%
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
50.05
34.95
231.46%

Broncus Holding Corp. Corporate Events

Broncus Holding Corp. Gains Approval for Innovative Lung Cancer Treatment System in China
Jun 23, 2025

Broncus Holding Corporation has announced that its BroncAblate® Lung Radiofrequency Ablation Generator has been approved for marketing in China by the National Medical Products Administration. This approval marks a significant step for the company as it begins the commercialization of the world’s first natural orifice transluminal radiofrequency ablation system for lung cancer. The system, which combines the BroncAblate® Generator and Catheter, offers a less invasive treatment option for lung tumors, potentially improving patient outcomes with fewer complications. This development positions Broncus Holding Corporation as a pioneer in the field of interventional lung cancer therapies, filling a global gap with its innovative approach.

Broncus Holding Corp. AGM Resolutions Passed with Strong Shareholder Support
May 16, 2025

Broncus Holding Corp. announced the successful passage of all ordinary resolutions at its annual general meeting held on May 16, 2025. This includes the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting mandates for share issuance and buyback. The approval of these resolutions reflects strong shareholder support and positions the company for continued strategic operations and governance.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 22, 2025